CLINICAL TRIALS PROFILE FOR SCANLUX-370

All Clinical Trials for SCANLUX-370

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04375787 ↗	Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention	Completed	Mohamed Abdelfatah	Phase 4	2020-03-15	Investigate of the potential benefit of acute pretreatment with high dose atorvastatin (80 mg) in reduction of the incidence of CIN in diabetic patients indicated for elective coronary intervention.
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	Breast Cancer Research Foundation	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	QED Therapeutics, Inc.	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	Stanford University	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)

Clinical Trial Conditions for SCANLUX-370

Condition Name

Condition Name for SCANLUX-370
Intervention	Trials
Breast Cancer	1
Coronary Disease	1
ER Positive Breast Cancer	1
ER-Negative Breast Cancer	1

Condition MeSH

Condition MeSH for SCANLUX-370
Intervention	Trials
Breast Neoplasms	1
Coronary Disease	1

Clinical Trial Locations for SCANLUX-370

Trials by Country

Trials by Country for SCANLUX-370
Location	Trials
Egypt	1
United States	1

Trials by US State

Trials by US State for SCANLUX-370
Location	Trials
California	1

Clinical Trial Progress for SCANLUX-370

Clinical Trial Phase

Clinical Trial Phase for SCANLUX-370
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for SCANLUX-370
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for SCANLUX-370

Sponsor Name

Sponsor Name for SCANLUX-370
Sponsor	Trials
Mohamed Abdelfatah	1
Breast Cancer Research Foundation	1
National Cancer Institute (NCI)	1

Sponsor Type

Sponsor Type for SCANLUX-370
Sponsor	Trials
Other	3
NIH	1
Industry	1

SCANLUX-370 clinical trials update and market projection: status, key studies, and commercial outlook

Last updated: July 24, 2026

What is SCANLUX-370 and what indication is it in?

SCANLUX-370 clinical development status, mechanism of action, indication, sponsoring company, and trial identifiers are not provided. Without confirmed drug identity attributes (active ingredient, sponsor, target, or study registry entries), no accurate clinical-trials update or market forecast can be produced.

What clinical trials are ongoing for SCANLUX-370?

No validated clinical trial record for SCANLUX-370 (NCT/CTRI/DRKS/EudraCT), dosing regimen, phase, recruitment status, or endpoints is available in the provided information. A compliant “ongoing trials” update requires verified registry data.

What are the latest results and milestones for SCANLUX-370?

No latest readout date, interim analysis, primary endpoint, response rate, safety signal, or sponsor guidance is available for SCANLUX-370 in the provided information. A results and milestones section needs primary-source evidence.

When will SCANLUX-370 complete Phase 2 or Phase 3?

No study completion dates, protocol amendment history, regulatory timelines, or SPA/Type C feedback references are provided for SCANLUX-370.

Is SCANLUX-370 on track for FDA approval, and what regulatory pathway is planned?

No regulatory pathway details (e.g., Breakthrough Therapy, Fast Track, RMAT, accelerated approval), target population, or FDA meeting history are provided for SCANLUX-370.

What is the Orange Book status of SCANLUX-370?

Orange Book listing status is not determinable because SCANLUX-370’s approved drug name, NDA/BLA holder, and NDC/ingredients are not supplied. Orange Book status requires an FDA product identifier.

What patents protect SCANLUX-370?

No patent estate inputs are provided (active ingredient, assignee(s), core composition-of-matter, formulation, method-of-use, or manufacturing process patents). Patent protection cannot be mapped without confirmed chemical or publication identifiers.

Which companies are challenging SCANLUX-370 with Paragraph IV ANDAs?

No ANDA/Paragraph IV challenge data are provided, and without Orange Book-linked patents and product identifiers, no challenge landscape can be compiled.

What generic entry risks exist for SCANLUX-370?

Generic entry risk requires (1) approved product status, (2) listed patents and expiration dates, and (3) any active litigation. None of these inputs are provided.

How many patents cover SCANLUX-370, and when do they expire?

No patent numbers or expiry dates are provided.

What formulation patents protect SCANLUX-370 dosing and delivery?

No dosage form, formulation details, or related IP are provided.

What method-of-use patents protect SCANLUX-370?

No labeled indication, patient population definition, endpoints, or use claims are provided to anchor a method-of-use landscape.

What patent litigation affects SCANLUX-370?

No litigation docket, venue, case caption, asserted patents, or settlement dates are provided.

What settlement agreements or exclusivity events shape SCANLUX-370 timelines?

No settlement or exclusivity events are provided.

How does SCANLUX-370 compare with competing drugs in its class?

No indication or competitor set is provided. Comparative assessment requires confirmed target, line of therapy, dosing schedule, and trial outcome comparators.

What is the market size for SCANLUX-370 and how is adoption projected?

No indication, geography, payer model, pricing assumptions, or patient-eligibility criteria are provided. A market model cannot be built without a therapeutic area and confirmed clinical efficacy and safety profile.

What revenue projection scenarios apply to SCANLUX-370?

Revenue projection requires at minimum: approval probability by phase, expected launch year, annual eligible population, penetration curve, price, and competitive dynamics. None of these inputs are available.

Key Takeaways

• No verified clinical-trials, regulatory, patent, or market inputs for SCANLUX-370 are available in the provided information, so a fact-based clinical update and market projection cannot be produced.

FAQs

1. What does SCANLUX-370’s mechanism target in disease?
2. What are the NCT identifiers for SCANLUX-370 trials?
3. When is SCANLUX-370 expected to report top-line Phase 2 data?
4. Is SCANLUX-370 eligible for accelerated approval or RMAT/Fast Track?
5. What is the projected launch revenue range for SCANLUX-370 by scenario?

References

No sources were provided or cited.